

Title (en)
TREATMENT OF IBD USING BOTH PROBIOTIC BACTERIA AND FERMENTED CEREAL AS TREATMENT EFFECTORS

Title (de)
BEHANDLUNG VON ENTZÜNDLICHER DARMERKRANKUNG MIT PROBIOTISCHEN BAKTERIEN UND FERMENTIERTEN CEREALIEN ALS BEHANDLUNGSEFFEKTOREN

Title (fr)
TRAITEMENT DES MALADIES INTESTINALES INFLAMMATOIRES PAR L'UTILISATION, EN TANT QU'EFFECTEURS THÉRAPEUTIQUES, DE BACTÉRIES PROBIOTIQUES ET DE CÉRÉALES FERMENTÉES

Publication
EP 1931363 A1 20080618 (EN)

Application
EP 06776003 A 20060927

Priority

- DK 2006000526 W 20060927
- EP 05388079 A 20050928
- US 72127605 P 20050928
- DK PA200600529 A 20060412
- US 74471706 P 20060412
- EP 06776003 A 20060927

Abstract (en)
[origin: WO2007036230A1] The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

IPC 8 full level
A23L 1/172 (2006.01); **A23L 1/30** (2006.01); **A23L 7/152** (2016.01); **A61K 31/685** (2006.01); **A61K 35/74** (2015.01); **A61K 35/745** (2015.01); **A61K 35/747** (2015.01)

CPC (source: EP US)
A23L 7/152 (2016.07 - EP US); **A23L 33/135** (2016.07 - EP US); **A61K 31/196** (2013.01 - EP US); **A61K 31/685** (2013.01 - EP US); **A61K 35/66** (2013.01 - EP US); **A61K 35/74** (2013.01 - EP US); **A61K 35/742** (2013.01 - EP US); **A61K 35/744** (2013.01 - EP US); **A61K 35/745** (2013.01 - EP US); **A61K 35/747** (2013.01 - EP US); **A61K 36/899** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/06** (2017.12 - EP); **A61P 1/10** (2017.12 - EP); **A61P 1/12** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **A23V 2002/00** (2013.01 - EP US); **A23V 2200/3204** (2013.01 - EP US); **A61K 2035/115** (2013.01 - US); **Y02A 90/10** (2017.12 - EP US)

Citation (search report)
See references of WO 2007036230A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2007036230 A1 20070405; AU 2006296837 A1 20070405; AU 2006296837 B2 20121213; CA 2622951 A1 20070405; DK 1931363 T3 20160222; DK 2277524 T3 20160208; DK 3067057 T3 20230213; EP 1931363 A1 20080618; EP 1931363 B1 20151118; EP 2277524 A1 20110126; EP 2277524 B1 20151111; EP 3067057 A1 20160914; EP 3067057 B1 20221109; ES 2561584 T3 20160229; ES 2561629 T3 20160229; JP 2009509981 A 20090312; JP 2013136644 A 20130711; JP 2013144712 A 20130725; JP 2015163643 A 20150910; JP 5363811 B2 20131211; JP 5706461 B2 20150422; JP 5802235 B2 20151028; JP 6150353 B2 20170621; PL 1931363 T3 20160630; PL 2277524 T3 20160630; SI 1931363 T1 20160229; SI 2277524 T1 20160229; US 10286026 B2 20190514; US 2008311097 A1 20081218; US 2012269791 A1 20121025; US 2013195821 A1 20130801; US 2013209404 A1 20130815; US 2015359836 A1 20151217; US 2017333514 A1 20171123; US 8846029 B2 20140930; US 8900570 B2 20141202; US 9205114 B2 20151208

DOCDB simple family (application)
DK 2006000526 W 20060927; AU 2006296837 A 20060927; CA 2622951 A 20060927; DK 06776003 T 20060927; DK 10182284 T 20060927; DK 15194713 T 20060927; EP 06776003 A 20060927; EP 10182284 A 20060927; EP 15194713 A 20060927; ES 06776003 T 20060927; ES 10182284 T 20060927; JP 2008532598 A 20060927; JP 2013082426 A 20130410; JP 2013082427 A 20130410; JP 2015113693 A 20150604; PL 06776003 T 20060927; PL 10182284 T 20060927; SI 200632021 T 20060927; SI 200632022 T 20060927; US 201213540827 A 20120703; US 201313826076 A 20130314; US 201313826208 A 20130314; US 201514834639 A 20150825; US 201715433982 A 20170215; US 6624606 A 20060927